Table 1.
Characteristics of the study participants
| n (Female : male) | 281 (107:174) |
|---|---|
| Age (years) | 68 (62–71) |
| Duration of diabetes (years) | 13 (7–23) |
| BMI (kg/m2) | 24.1 (22.0–26.9) |
| HbA1c (%) | 6.9 (6.5–7.5) |
| eGFR (mL/min/1.73 m2) | 71.5 (60.9–82.0) |
| UACR (mg/gCr) | 14.1 (6.1–46.2) |
| Hypertension | 177 (63.0%) |
| Dyslipidemia | 227 (80.8%) |
| CGM | |
| Mean sensor glucose (mg/dL) | 137.4 (119.2–159.0) |
| SD (mg/dL) | 36.7 (29.9–45.0) |
| CV (%) | 26.4 (22.4–30.6) |
| TIR70–180 (%) | 78.9 (66.9–90.4) |
| TAR>180 (%) | 15.5 (6.6–30.5) |
| TAR>250 (%) | 0.8 (0–4.5) |
| TBR<70 (%) | 0.3 (0–2.5) |
| TBR<54 (%) | 0 (0–0.2) |
| HBGI | 3.5 (2.2–5.6) |
| LBGI | 0.9 (0.4–2.0) |
| Antidiabetic drugs | |
| Metformin | 152 (54.1%) |
| Sulfonylureas | 55 (19.6%) |
| Glinides | 23 (8.2%) |
| Thiazolidines | 23 (8.2%) |
| α‐Glucosidase inhibitors | 52 (18.5%) |
| DPP‐4 inhibitors | 149 (53.0%) |
| SGLT2 inhibitors | 72 (25.6%) |
| Insulin | 74 (26.3%) |
| GLP‐1 receptor agonists | 37 (13.2%) |
The results are shown as the median values (interquartile range). BMI, body mass index; CGM, continuous glucose monitoring; CV, coefficient of variation; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; HBGI, high blood glucose index; LBGI, low blood glucose index; SD, standard deviation; SGLT2, sodium–glucose cotransporter 2; TAR, time above range; TBR, time below range; TIR, time in range; UACR, urine albumin‐to‐creatinine ratio.